For the quarter ending 2026-01-31.
| Income Statement | 2026-01-31 | 2025-10-31 | 2025-07-31 | 2025-04-30 |
|---|---|---|---|---|
| Total revenue-Infusion Technology | - | - | -33* | - |
| Total revenue-Rental Third Party | - | - | 50* | - |
| Total revenue | 211 | 240 | 182* | 362 |
| Total revenue-Rental Related Party | - | - | 28* | - |
| Total revenue-Product Revenue | - | - | -214* | - |
| Cost of product revenue-Infusion Technology Revenue | - | - | 13* | - |
| Cost of revenue | 12 | 9 | 1* | - |
| Cost of product revenue | - | - | - | 40 |
| General and administrative | 2,270 | 2,838 | 5,242* | 3,170 |
| Research and development | 4,529 | 7,484 | 8,148* | 3,003 |
| Depreciation and amortization | 55 | 50 | 66* | 62 |
| In-process research and development expense | - | - | 0* | - |
| Loss on impairment of goodwill | 0 | - | 775* | - |
| Loss from operations | -6,655 | -10,141 | -14,231* | -5,913 |
| Unrealized (gain) loss on investment - cyclo | - | - | 3,493* | -1,393 |
| Interest income | 337 | 399 | 436* | 472 |
| Unrealized (gain) loss on convertible notes receivable, due from cyclo | - | - | 1,089* | 383 |
| Interest expense | 161 | 160 | 168* | 165 |
| Gain on settlement of accounts payable and convertible notes payable | 201 | - | - | - |
| Other (loss) income, net | -1 | 115 | 82* | 154 |
| Loss on initial investment in day three upon acquisition | - | - | 0* | - |
| Realized loss on investment in equity securities | - | - | 0* | - |
| Realized gain on investment - cyclo | - | - | 0* | - |
| Realized (gain) loss on available-for-sale securities | 0 | 0 | -404* | - |
| Unrealized gain on investment - hedge funds | - | - | 0* | - |
| Unrealized gain (loss) on investment - cyclo | 0 | 0 | - | - |
| Recovery of receivables from cornerstone | - | - | 0* | - |
| Unrealized gain (loss) on convertible notes receivable, due from cyclo | 0 | 0 | - | - |
| Loss before income taxes | -6,279 | -9,787 | -9,703* | -6,462 |
| Equity in loss of day three | - | - | 0* | - |
| Provision for income taxes | 48 | 10 | 1,046* | -2,411 |
| Consolidated net loss | -6,327 | -9,797 | -10,749* | -4,051 |
| Net income (loss) attributable to noncontrolling interests | 90 | 19 | -907* | 728 |
| Net loss attributable to rafael holdings, inc | -6,417 | -9,816 | -9,842 | -4,779 |
| Basic EPS | -0.13 | -0.19 | -0.253 | -0.19 |
| Diluted EPS | -0.13 | -0.19 | -0.253 | -0.19 |
| Basic Average Shares | 51,226,095 | 51,184,407 | 38,965,308 | 25,238,501 |
| Diluted Average Shares | 51,226,095 | 51,184,407 | 38,965,308 | 25,238,501 |
Rafael Holdings, Inc. (RFL)
Rafael Holdings, Inc. (RFL)